# Inhalable, Room-Temp, Needle-Free: Immuno‑Nanomed's Vaccine Moonshot

Page: https://stenobird.com/podcast/iowa-tech-podcast-7097920/inhalable-room-temp-needle-free-immuno-nanomed-s-vaccine-moonshot
Text version: https://stenobird.com/podcast/iowa-tech-podcast-7097920/inhalable-room-temp-needle-free-immuno-nanomed-s-vaccine-moonshot.md
Podcast: [Iowa Tech Podcast](https://stenobird.com/podcast/iowa-tech-podcast-7097920)
Published: 2026-02-10T14:01:00+00:00
Episode link: https://f8302322-1d6c-46da-acd0-a4cdad4ddaab.libsyn.com/inhalable-room-temp-needle-free-immunonanomeds-vaccine-moonshot
Audio file: https://traffic.libsyn.com/secure/f8302322-1d6c-46da-acd0-a4cdad4ddaab/Tech_Interview_with_Balaji.mp3?dest-id=4673877
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/iowa-tech-podcast-7097920/episodes/inhalable-room-temp-needle-free-immuno-nanomed-s-vaccine-moonshot
Duration seconds: 1629

## Resource

On this episode of the Iowa Tech Podcast, host Kaylee sits down with Dr. Balaji Narasimhan, CEO and founder of ImmunoNanoMed, to explore a moonshot innovation: a dry-powder, needle-free vaccine platform called "powder wax" that's inhaled through the nose. Balaji explains how their particle-based technology could deliver stronger, faster mucosal immunity right where respiratory pathogens take hold, improve protection against variants, and eliminate the cold chain—potentially slashing costs and enabling at-home, self-administered vaccination. He also shares how the platform could multiplex vaccines (think flu, RSV, COVID, pneumonia) and extend to companion animals and even livestock and poultry via mass-vaccination approaches, with an eye toward DIVA compatibility and safeguarding human health supply chains. 💡 Find this show on your favorite player: https://iowapodcast.com/immunonanomed... 🗞️ Be first to get new interviews: https://iowapodcast.com/subscribe/ 🐖 Get a free $30 gift card from Jethro's BBQ: https://iowapodcast.com/jethrosbbq Balaji traces the technology's origins to a Seahawk collaboration between Iowa State University and the University of Iowa, then details ImmunoNanoMed's path from lab success to commercialization: building a cross-functional team, partnering with CROs to get FDA-ready, pursuing scalable, high-quality manufacturing, and engaging potential big-pharma partners—all targeted over the next 6–18 months. He reflects on Iowa's innovation ecosystem (Startup Factory, I-Corps, IEDA, InnoVenture) and why he's committed to proving world-class health tech can emerge from the Midwest. The episode closes with personal notes on mentors, teamwork, and family, plus a call for collaborators. Learn more or get in touch at immunonanomed.com. Chapters: 00:00 In…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/iowa-tech-podcast-7097920/episodes/inhalable-room-temp-needle-free-immuno-nanomed-s-vaccine-moonshot/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/iowa-tech-podcast-7097920/inhalable-room-temp-needle-free-immuno-nanomed-s-vaccine-moonshot.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.